Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Small Cell Lung Carcinoma 3Multiple Myeloma 2Wilms Tumor 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neuroblastoma 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1Carcinoma, Merkel Cell 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Cyclophosphamide 153Dexamethasone 140Rituximab 83fludarabine 79Cytarabine 69Lenalidomide 68Bortezomib 64fludarabine phosphate 62Gemcitabine 62venetoclax 55Etoposide 53pembrolizumab 52pomalidomide 49Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Recurrence × lorvotuzumab mertansine × Clear all
NCT00991562 2014-11-21

IMGN901 in Combination With Lenalidomide and Dexamethasone

ImmunoGen, Inc.

Phase 1 Completed
50 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡